Two things happen to the stomach at the same time on a GLP-1 protocol. It empties more slowly, which makes reflux more likely. And the body around it gets lighter, which makes reflux less likely. The first effect arrives in days. The second takes months.
That timing mismatch is the whole story of heartburn on semaglutide and tirzepatide. In the phase 3 obesity trials, reflux was reported by roughly 5 percent of people on the drug against 3 percent on placebo, and dyspepsia, belching and bloating ran two to three times the placebo rate. Those are modest excesses in the averages. What the averages hide is that the complaints cluster in the first two to four weeks and around each dose increase, then settle for most people as gastric emptying partially adapts and as weight comes down.
Someone who already had reflux before starting, or who has a hiatal hernia, is in a different position from someone whose oesophagus has never been troubled. Both groups benefit from understanding which direction the two forces are pulling at any given week, and from knowing which symptoms are a nuisance and which are a reason to be examined.
Key Takeaways
- Gastro-oesophageal reflux was reported by about 5 percent of participants on semaglutide 2.4 mg in the STEP trials versus about 3 percent on placebo. Tirzepatide in SURMOUNT-1 produced a similar excess of roughly 4 to 5 percent against 3 percent. Dyspepsia, belching and bloating were each reported two to three times as often as on placebo.
- The mechanism is delayed gastric emptying. A fuller stomach stretches its upper wall and triggers more transient relaxations of the lower oesophageal sphincter, which is the main mechanical event behind reflux. A fuller stomach also holds more acidic content available to move upward when that sphincter opens.
- The emptying delay is largest in the first weeks and partially fades with continuous exposure. Pharmacology studies of GLP-1 receptor agonists show substantial attenuation of the delay for liquids over weeks of dosing, with a smaller persistent effect on solid meals of roughly 15 to 25 percent at 20 weeks.
- Sustained weight loss reduces reflux from the opposite direction. In a structured weight loss study, around 80 percent of participants who lost roughly 10 percent of body weight had reflux scores improve, and about two thirds had symptoms resolve. Trial-average losses on semaglutide and tirzepatide were 15 to 20 percent.
- Observational cohorts in people with type 2 diabetes have associated GLP-1 receptor agonist use with a higher rate of reflux diagnoses and erosive oesophagitis than comparator glucose-lowering drugs, with hazard ratios in the range of roughly 1.2 to 1.5. These are observational comparisons with confounding by indication and no weight loss adjustment.
- No trial has tested a reduced dose or a longer escalation schedule against a reflux endpoint. The argument that a gentler ramp reduces early reflux is an inference from the timing of adverse events around escalation steps, not a demonstrated result.
How Often Was Reflux Reported in the Obesity Trials?
Approximate percent of participants reporting each upper GI event over 68 weeks, semaglutide 2.4 mg arm versus placebo arm
- Semaglutide 2.4 mg
- Placebo
Approximate pooled figures in the direction of the semaglutide 2.4 mg prescribing information and STEP trial reporting, rounded rather than exact. Nausea is included for scale. Reflux itself is the smallest excess on the chart, and belching is the largest relative one, which fits a stomach that is holding more gas and content for longer rather than one producing more acid.
Why does a GLP-1 medication cause heartburn?
A pressure problem, not an acid problem
GLP-1 receptor agonists cause reflux by slowing gastric emptying, not by increasing acid production. The stomach on semaglutide or tirzepatide holds a meal for longer, and a stomach that stays full stretches the region just below the oesophagus. That stretch is the trigger for transient lower oesophageal sphincter relaxations, which are brief openings of the valve between oesophagus and stomach that occur outside of swallowing. In most people with reflux, those transient relaxations rather than a permanently weak valve are the main mechanical event, and they happen more often when the stomach is distended.
A fuller stomach also means more content is available to travel upward when the sphincter opens. Acid secretion is not increased by GLP-1 receptor activation, and some evidence suggests it is mildly reduced. The problem is entirely that the acid and food that would normally have moved into the small intestine are still sitting in the stomach, under pressure, at the moment the valve relaxes.
This is why belching and bloating outnumber true heartburn in the trial reporting. Swallowed air and gas from fermentation accumulate in a stomach that is not passing contents along at its usual rate, and belching is the sphincter opening to vent it. Every one of those openings is also an opportunity for acid to follow.
What Does the Reflux Curve Look Like Over a Year?
Illustrative reflux symptom score on a 0 to 100 scale, separating the stomach-side push from delayed emptying and the pressure-side pull from weight loss
- Stomach-side effect only
- Weight-loss effect only
- Net symptom score
Constructed trajectories illustrating the shape described in the gastric emptying and weight loss literatures, not measured data from any cohort. The dashed horizontal line is the starting score. The net line crosses back below it around week twelve, which is roughly where the emptying delay has partly faded and the weight loss has become large enough to matter.
Does the stomach adapt, and how much?
Partial tolerance, not full recovery
The delay in gastric emptying produced by GLP-1 receptor agonists lessens with continued exposure, but it does not disappear. Nauck and colleagues showed in 2011 that the emptying delay from continuous GLP-1 infusion for liquid meals faded substantially over a single day of exposure, a phenomenon usually described as tachyphylaxis of the vagal reflex involved. Longer-acting agents show the same direction over weeks. With semaglutide, a paracetamol absorption study found the delay in the first hour after a solid meal was still present at steady state but modest, in the region of a quarter reduction in early absorption.
That pattern explains the shape of the complaints. The first two to four weeks on any dose are when the stomach is slowest and the sphincter is under the most strain. Each escalation step resets part of that adaptation, which is why reflux, nausea and bloating tend to return briefly at each step-up and then settle again. By the time someone reaches a stable maintenance dose, the emptying delay is a fraction of what it was and has become a background feature rather than a daily one.
Adaptation is incomplete for solids, and this matters for anyone with pre-existing reflux. A residual delay of 15 to 25 percent on a large evening meal is enough to keep the stomach distended at bedtime, which is the single worst time for the sphincter to be under pressure because lying flat removes gravity from the equation.
How Much Does the Emptying Delay Fade With Continued Dosing?
Approximate delay in solid meal gastric emptying relative to baseline, in percent, across weeks of continuous GLP-1 receptor exposure
Approximate values illustrating the attenuation described across pharmacology studies of long-acting GLP-1 receptor agonists rather than serial measurements from one trial. The highlighted bars are the window in which reflux complaints cluster. The delay roughly halves by week twelve and then plateaus rather than returning to zero.
How does weight loss reduce reflux?
The pull from the other direction
Body weight is one of the strongest modifiable drivers of reflux, and losing it reduces symptoms in a dose-dependent way. In the Nurses' Health Study, an increase in body mass index of about 3.5 units was associated with nearly a threefold rise in the odds of frequent reflux symptoms, and the relationship held even within the normal weight range. Abdominal fat raises pressure inside the abdomen, which raises pressure inside the stomach, which increases the gradient pushing contents up through the sphincter. Higher abdominal pressure also promotes hiatal hernia, where the upper stomach slides into the chest and the sphincter loses the mechanical support of the diaphragm.
Reversing that pressure reverses the symptoms. A structured weight loss study by Singh and colleagues in 2013 followed participants who lost an average of about 13 kilograms, roughly 10 percent of body weight, and found that reflux scores improved in about 80 percent and resolved in about two thirds, with the size of the improvement tracking the size of the weight loss. Trial-average losses on semaglutide 2.4 mg were around 15 percent, and on tirzepatide at the highest dose around 20 percent, both well past the threshold at which that study observed benefit.
This is the reason the long-run direction of the curve is favourable for most people. The stomach-side effect is a fixed-size push that fades. The pressure-side effect is a pull that grows with every kilogram and does not fade as long as the weight stays off. Nobody has measured the two against each other in a GLP-1 trial with a reflux endpoint, so the crossover point in the chart above is an inference rather than a finding.
How Closely Does Reflux Track Body Weight?
Approximate prevalence of at least weekly reflux symptoms as a percent, by body mass index band
Approximate band prevalences reflecting the direction and rough magnitude of population survey reporting rather than values from a single dataset. The gradient across the bands is why sustained weight loss is a reflux intervention in its own right, and it is what makes the early weeks of a GLP-1 protocol feel like the wrong direction of travel.
Who is most likely to get reflux on a GLP-1 protocol?
Four groups, of unequal concern
The excess reflux in the trials was small on average, and most of it landed on people with a reason to be susceptible. The four groups below account for most of the complaints that persist beyond the first month.
People with reflux before starting
An oesophagus that is already exposed to acid regularly has less reserve, and a stomach that empties 30 to 40 percent slower in the first weeks adds load to a system that was already near its limit. The trials did not exclude people with reflux, and the excess in the drug arms is likely concentrated among them, though subgroup data by baseline reflux status have not been published in detail. Anyone on a daily acid suppressant before starting should say so, since it changes how the early weeks are planned.
People with a hiatal hernia
A hiatal hernia removes the diaphragm's contribution to the sphincter and creates a pocket of stomach above it that fills and refluxes readily. Delayed emptying keeps that pocket fuller for longer. Hiatal hernia is common in people with higher body weight and is often undiagnosed, so a history of reflux that responds poorly to acid suppression or that produces regurgitation of food rather than just burning is worth mentioning to a prescriber.
People who eat a large meal late in the evening
Lying flat within two to three hours of a large meal is the highest-risk situation for reflux in anyone, and a GLP-1 medication extends the window during which the stomach is still full. The trial adverse event reports do not capture meal timing, but the mechanism makes the evening meal the single most important one to keep small and early during the first weeks and at each dose step.
People whose escalation is fast or whose dose is high
Upper GI events in the phase 3 programmes were broadly dose related, with nausea and dyspepsia rising across the tirzepatide 5, 10 and 15 mg arms and reflux showing a smaller gradient. Each escalation step partly resets the emptying adaptation. This is the mechanistic basis for the argument that a slower ramp or a lower ceiling reduces early reflux, and it is also the argument that has not been tested against a reflux endpoint.
When Do Upper GI Complaints First Appear?
Approximate share of first-time upper GI complaints beginning in each window of a GLP-1 protocol, in percent
Approximate distribution reflecting the pattern described in trial adverse event timing rather than a tabulated onset analysis from any single study. More than half of first complaints begin in the first month, and most of the remainder begin within days of a dose increase. A complaint that starts fresh after week sixteen on a stable dose does not fit this pattern and deserves a closer look.
What actually reduces reflux during the early weeks?
Six measures, ranked by the size of their evidence
The measures that reduce reflux on a GLP-1 protocol are the same ones that reduce reflux generally, because the mechanism is the same: a stomach that is full at the wrong time. Raising the head of the bed by 15 to 20 centimetres, sleeping on the left side, keeping the last meal at least three hours before lying down, and making that meal smaller and lower in fat each have support in controlled studies of people with reflux. Fat delays gastric emptying on its own, which stacks with the medication.
Carbonated drinks and alcohol are worth removing from the evening during the early weeks. Carbonation adds gas to a stomach that is already venting more than usual, and alcohol relaxes the sphincter directly. Neither has been studied specifically alongside a GLP-1 medication, and both have consistent effects on reflux in general.
Proton pump inhibitors and H2 blockers are the most effective single measure for symptoms and are commonly used alongside these medications, but starting one is a prescribing decision and using an over-the-counter version daily to tolerate a dose is information the prescriber needs. Acid suppression treats the acid, not the distension, so it is a partial fix for a mechanical problem.
Which Measures Reduce Reflux, and By How Much?
Approximate reduction in reflux symptom burden as a percent, by intervention, in people with established reflux
Approximate central estimates assembled from separate studies in different populations, comparable in direction and rough scale rather than head to head. The highlighted bar is the one a GLP-1 protocol eventually delivers on its own. The four smallest bars are the ones available in week one, and they add up.
What is worth documenting and raising with a prescriber?
Six observations, none of which are a treatment plan
Everything below is information worth gathering and questions worth asking. None of it sets a dose, changes a medication, or replaces an assessment. Chest pain in particular has causes that are not reflux and cannot be distinguished from it without examination.
A history of weekly heartburn, regurgitation, or a diagnosed hiatal hernia changes how the first weeks should be planned and whether acid suppression is worth having in place before rather than after the first dose. People frequently underreport reflux because they regard it as normal. A prescriber weighing escalation pace is weighing a different question for someone with an already-loaded oesophagus than for someone without. This one sentence changes the assessment more than anything else on this list.
Reflux that begins within days of a step-up and settles within two to three weeks fits the emptying adaptation pattern and is usually managed by pacing. Reflux that starts fresh after months on a stable dose does not fit and needs a different explanation. Writing down the date of each dose change and the date each new symptom began is the cheapest diagnostic information available and it is almost never recorded.
Calcium channel blockers, nitrates, some antidepressants, bisphosphonates, and non-steroidal anti-inflammatories all either relax the sphincter or irritate the oesophagus directly, and their effects stack with delayed emptying. Delayed emptying can also change the absorption timing of oral medications, which is a separate conversation covered elsewhere on this site. The prescriber needs the whole list to weigh any of it.
Difficulty or pain on swallowing, vomiting blood or coffee-ground material, black tarry stools, persistent vomiting, chest pain, and new anaemia are the recognised features that move a reflux complaint from managing to examining. These indicate possible oesophageal injury, bleeding, or another cause entirely. Agreeing in advance who to call and what the plan is turns a frightening night into a phone call.
Proton pump inhibitors are effective and widely used alongside GLP-1 medications, and they also carry long-term considerations that belong with a prescriber. Stopping one abruptly produces rebound acid secretion that can be mistaken for the medication getting worse. Needing an over-the-counter product every day to tolerate a dose is a signal about the dose, not a solution to it.
This is the one measure on the list that requires nobody's permission and targets the mechanism directly. A stomach that is 30 to 40 percent slower in the first weeks needs more time between the last meal and lying down, and fat slows emptying further on its own. Raising the head of the bed and sleeping on the left side address the same problem from the other end. None of this substitutes for review if symptoms persist.
What is genuinely unresolved here?
Three gaps worth naming
The observational signal for erosive oesophagitis has not been reconciled with the weight loss data. Several large cohort analyses in people with type 2 diabetes, including a 2024 analysis of a multi-institution electronic health record network, associated GLP-1 receptor agonist use with a higher rate of reflux diagnoses and of erosive oesophagitis than comparator glucose-lowering agents, with hazard ratios in the range of roughly 1.2 to 1.5. Those cohorts were diabetes populations using lower doses than the obesity trials, they were not adjusted for how much weight was lost, and confounding by indication is unavoidable. A signal that size is real enough to take seriously and too confounded to interpret on its own.
No trial has tested a reduced dose or a slower escalation against a reflux endpoint. The mechanistic case is coherent, since a smaller step means a smaller reset of the emptying adaptation, and it remains untested. A slower ramp also delays the weight loss that produces the pressure-side benefit. Whether that trade is worth making for a given person is not something the published literature can currently answer.
The crossover point in the trajectory chart is an inference. Nobody has followed a cohort on a GLP-1 medication with validated reflux scores at regular intervals across a year, so the week at which the pressure-side pull overtakes the stomach-side push is a prediction from two separate literatures rather than an observation from one. It is a reasonable prediction. It is not a measurement.
Frequently Asked Questions
Selected References
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021. Gastrointestinal adverse event reporting including reflux, dyspepsia and eructation.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022. Dose-related upper GI adverse events across 5, 10 and 15 mg arms.
- Nauck MA et al. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes, 2011.
- Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism, 2018.
- Jacobson BC, Somers SC, Fuchs CS, Kelly CP, Camargo CA. Body mass index and symptoms of gastroesophageal reflux in women. New England Journal of Medicine, 2006.
- Singh M et al. Weight loss can lead to resolution of gastroesophageal reflux disease symptoms, a prospective intervention trial. Obesity, 2013.
- Ness-Jensen E, Hveem K, El-Serag H, Lagergren J. Lifestyle intervention in gastroesophageal reflux disease. Clinical Gastroenterology and Hepatology, 2016. Head of bed elevation, meal timing and weight loss evidence review.
- Liu BD et al. Glucagon-like peptide-1 receptor agonists and the risk of gastroesophageal reflux disease and its complications in patients with type 2 diabetes. Retrospective cohort analysis, 2024.
- Mittal RK, Holloway RH, Penagini R, Blackshaw LA, Dent J. Transient lower esophageal sphincter relaxation. Gastroenterology, 1995. Mechanism of gastric distension triggering sphincter relaxation.
- Katz PO, Dunbar KB, Schnoll-Sussman FH et al. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology, 2022. Alarm features and management recommendations.
This article is for general educational purposes only and does not constitute medical advice, diagnosis, treatment, or a monitoring plan. Nothing here should be used to start, stop or adjust any medication, including acid suppressants, or to self-diagnose chest, throat or abdominal symptoms. GLP-1 medications are prescription drugs, and dose, escalation pace, and any low dose or microdosing approach should be decided and monitored by a qualified healthcare provider. Nothing here is intended to diagnose, prevent, treat, or cure gastro-oesophageal reflux disease, oesophagitis, hiatal hernia, obesity, diabetes, or any other condition, and no low dose or microdosing approach has been shown in trials to be safe or effective or to reduce reflux. Several charts here are constructed, approximate or illustrative rather than measured outcomes, and the figures cited are approximations of published reporting rather than exact values. Chest pain, difficulty swallowing, vomiting blood, black stools, or persistent vomiting require prompt medical assessment rather than self-management. Individual results vary.
Smaller Doses. Sharper Protocols.
Metabolic health you can measure, built around a dose designed to work with your body rather than against it.
Find Your Protocol